non-puerperal mastitis
Conditions
Interventions
Rifampicin treatment group:Rifampicin 450mg/d
Rifampicin, isoniazid, ethambutol treatment group:rifampicin (450 mg/day), isoniazid (300 mg/day) and ethambutol (750 mg/day)
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
15 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18-75 years; 2. Primary patients with histopathologically confirmed GLM or PDM; 3. ECOG score: 0-1; 4. No pregnancy planned within 3 years; 5. Voluntary enrolment in the study and signed informed consent form
Exclusion criteria
Exclusion criteria: 1. Previous history of tuberculosis; 2. History of isoniazid, rifampicin, or ethambutol administration; 3. Pathology that fails to clarify GLM or PDM or other combined breast infections 4. Abnormalities of the blood system, liver and kidney functions; 5. Severe heart, liver, lung, kidney etc. dysfunction 6. History of uncontrolled diabetes mellitus or hypertension; 7. History of mental illness 8. History of malignant tumour 9. Women who are pregnant or breastfeeding 10. Other subjects who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate;Remission rate;Recurrence rate;Quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactZhigang Yu
The Second Hospital of Shandong University
Outcome results
None listed